Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Felices

Showing results (41-50 of 77) with videos related to

Pageof 8
Sort By:
Gynecologic Oncology|November 10, 2020
Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancerErin Wesley, Locke D Uppendahl, Martin Felices, et al.
The Journal of Experimental Medicine|August 1, 2018
ARID5B regulates metabolic programming in human adaptive NK cellsFrank Cichocki, Cheng-Ying Wu, Bin Zhang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2025
The transcription factor BCL11B drives NK cell cytotoxicity and antitumor activityAkhilesh Kumar, Bin Zhang, Andrew Baldys, et al.
Journal for Immunotherapy of Cancer|September 26, 2022
TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activityMichael F Kaminski, Laura Bendzick, Rachel Hopps, et al.
Cancers|September 23, 2020
NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In VivoDaniel A Vallera, Soldano Ferrone, Behiye Kodal, et al.
The Journal of Experimental Medicine|May 13, 2026
Reprogramming endogenous NK circuits by highly efficient nonviral genome editingRih-Sheng Huang, Shee Kwan Phung, Darin Sumstad, et al.
Journal for Immunotherapy of Cancer|July 25, 2024
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cellsAnders W Matson, Rob Hullsiek, Kate J Dixon, et al.
The Journal of Clinical Investigation|May 22, 2020
Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host diseaseBishwas Shrestha, Kelly Walton, Jordan Reff, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cellsAnders W Matson, Rob H Hullsiek, Kate J Dixon, et al.
Blood Advances|June 27, 2018
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDSDhifaf Sarhan, Ludwig Brandt, Martin Felices, et al.
Pageof 8

Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
Gynecologic Oncology|November 10, 2020
Cytomegalovirus and systemic inflammation at time of surgery is associated with worse outcomes in serous ovarian cancerErin Wesley, Locke D Uppendahl, Martin Felices, et al.
The Journal of Experimental Medicine|August 1, 2018
ARID5B regulates metabolic programming in human adaptive NK cellsFrank Cichocki, Cheng-Ying Wu, Bin Zhang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2025
The transcription factor BCL11B drives NK cell cytotoxicity and antitumor activityAkhilesh Kumar, Bin Zhang, Andrew Baldys, et al.
Journal for Immunotherapy of Cancer|September 26, 2022
TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activityMichael F Kaminski, Laura Bendzick, Rachel Hopps, et al.
Cancers|September 23, 2020
NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In VivoDaniel A Vallera, Soldano Ferrone, Behiye Kodal, et al.
The Journal of Experimental Medicine|May 13, 2026
Reprogramming endogenous NK circuits by highly efficient nonviral genome editingRih-Sheng Huang, Shee Kwan Phung, Darin Sumstad, et al.
Journal for Immunotherapy of Cancer|July 25, 2024
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cellsAnders W Matson, Rob Hullsiek, Kate J Dixon, et al.
The Journal of Clinical Investigation|May 22, 2020
Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host diseaseBishwas Shrestha, Kelly Walton, Jordan Reff, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cellsAnders W Matson, Rob H Hullsiek, Kate J Dixon, et al.
Blood Advances|June 27, 2018
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDSDhifaf Sarhan, Ludwig Brandt, Martin Felices, et al.
Pageof 8